TNXP Tonix Pharmaceuticals Holding Corp. Insider Trading

Director Carolyn E. Taylor bought 1,415 shares of TNXP at $10.55; stock down -83.8% from 52-week high, insider's prior TNXP trade lost -53.6% over 90 days.

Carolyn E. Taylor purchased 1,415 shares at $10.55 on 2026-06-12, expanding her position by 338.5%, but the timing reflects a difficult market backdrop: the current price of $11.35 is -83.8% below the 52-week high of $69.97, and Taylor's prior open-market buy at TNXP on 2025-08-21 delivered a -53.6% return over 90 days. The stock has declined -18.0% in the past 30 days and -14.3% over 90 days, placing this purchase in a downtrend. Fundamentally, the company reported $-40,194,000.00 in net income last quarter and was unprofitable over its most recent full fiscal year, though annual revenue grew 29.8% year-over-year. The purchase occurs alongside cluster buying activity (2 other insiders bought within the past 14 days), which may indicate coordinated conviction or may simply reflect coincidental trading windows, but the pattern of losses on Taylor's prior trade at this ticker and the company's cash-burn trajectory suggest elevated caution is warranted.

Director Richard Newcomb Stillwell buys 5,000 shares of TNXP at $11.65; stock down -83.6% from 52-week high amid unprofitable operations.

Richard Newcomb Stillwell, a director at Tonix Pharmaceuticals, purchased 5,000 shares at $11.65 on 2026-06-08, establishing a position in a company currently trading at $11.46—83.6% below its 52-week high of $69.97. The company generated $6.9M in quarterly revenue but posted a net loss of $40.2M, indicating significant burn relative to sales despite 29.8% annual revenue growth. The stock has declined 18.7% over 30 days and 18.0% over 90 days, reflecting sustained pressure on the equity. This purchase by a director during a period of substantial price deterioration occurs in the context of an unprofitable operation and warrants examination of the director's historical transaction pattern and the company's path to profitability.

CEO Seth Lederman buys 5,000 TNXP shares at $11.79; stock down 83.6% from $69.97 high, now at $11.46.

Seth Lederman, Chief Executive Officer, purchased 5,000 shares at $11.79 on 2026-06-09, increasing his holdings by 124.8% from 4,005 to 9,005 shares. The purchase occurs with the stock trading at $11.46, down 83.6% from its 52-week high of $69.97 and declined 18.7% over the prior 30 days. At Tonix Pharmaceuticals, Lederman's three prior open-market purchases show mixed results: one trade posted +48.4% 30-day and +185.7% 90-day returns (2025-05-15), while the two most recent buys (March 2026) delivered negative 30-day and 90-day returns, with the latest showing -6.1% and -21.4% respectively. The company remains unprofitable with a net loss of $40.2M in the latest full fiscal year, though annual revenue grew 29.8% year-over-year to $6.9M in the most recent quarter. This purchase at a depressed absolute price level follows a steep recent drawdown and occurs amid unprofitable operations, warranting analysis of whether the CEO's conviction translates to shareholder value recovery.

CEO Lederman buys 5,000 shares of TNXP at $12.62; stock down -77.8% from 52-week high, up 13.1% vs transaction price at $13.68.

Seth Lederman, Chief Executive Officer of Tonix Pharmaceuticals, purchased 5,000 shares at $12.62 on 2026-03-31, increasing his holdings by 33.3% to 20,001 shares. The buy occurs in a company struggling with significant losses—most recent quarter shows net income of -$32.0M against revenue of $3.3M, though annual revenue growth stands at +29.8%. The transaction price of $12.62 sits near the 52-week low of $12.03, and the stock has rebounded 13.1% to a current price of $13.68; however, it remains -77.8% from its 52-week high of $61.57. Across his open-market history at other tickers, Lederman's prior buys averaged +185.7% over 90 days with a 100% win rate, though his same-ticker history at TNXP shows only one measurable prior buy (2025-05-15: +185.7% at 90d) alongside a more recent purchase on 2026-03-18 whose outcome is not yet measurable. The timing and magnitude of this purchase warrant monitoring against the company's profitability trajectory and prior stock volatility.

TNXP CEO SETH LEDERMAN bought 15,000 shares at $14.89 on 2026-03-18; stock now -77.0% from 52-week high of $61.57.

SETH LEDERMAN, Chief Executive Officer of Tonix Pharmaceuticals, purchased 15,000 shares at $14.89 on 2026-03-18 for $223,350.00, expanding his stake from 1 share to 15,001 shares. This transaction occurs as the stock trades 77.0% below its 52-week high of $61.57 and down 22.1% over the past 90 days. The company is unprofitable, reporting $-32,010,000.00 net income in its most recent fiscal year, though revenue grew 29.8% year-over-year to $3,290,000.00 in the latest quarter. Lederman's prior buy at this ticker on 2025-05-15 generated a +185.7% return over 90 days, and his cross-ticker track record shows 1 prior buy with a 100.00% 90-day win rate and +185.7% average 90-day return. The timing of this purchase relative to valuation weakness and the pattern of his prior well-timed entry at this same ticker merit close examination of the company's strategic positioning.

Director Taylor Carolyn E. purchased 418 shares of TNXP at $36.03 (initial stake); stock now -41.8% from 52-week high despite +29.9% annual revenue growth.

Taylor Carolyn E., a director, acquired 418 shares of Tonix Pharmaceuticals at $36.03 per share on August 21, 2025, representing an initial holding position in the company. The purchase occurred at a significant premium to the current price of $35.85 and well above the 52-week low of $7.38, but the stock remains substantially depressed at -41.8% below its 52-week high of $61.57. Against a backdrop of strong revenue growth of +29.9% year-over-year, the company reported a net loss of $-28.3M in its most recent full fiscal year, indicating ongoing profitability challenges that may weigh on near-term investor sentiment. The combination of an insider director's initiation of a position alongside elevated cash burn and a sharply pullback price warrants investor monitoring of both the company's path to profitability and any material operational developments.

Director Treco James buys 250 TNXP shares at $36.00; stock down 20.1% in 30 days, trading -41.4% from 52-week high

Treco James purchased 250 shares at $36.00, establishing an initial position in Tonix Pharmaceuticals, which is currently unprofitable with net income of $-28.3M against quarterly revenue of $2.0M. The stock has declined 20.1% over the past 30 days and is substantially below its 52-week high of $61.57, trading at $36.05 currently—the purchase price is at the low end of recent activity. Despite recent weakness, the company has posted annual revenue growth of 29.9%, suggesting underlying business momentum. The modest transaction size ($9.0K) and founder's first-time accumulation merit monitoring to see whether this initial purchase signals broader conviction or is an exploratory position in a volatile, loss-making biotech.

CEO LEDERMAN bought 4,000 shares of TNXP at $21.55; holdings now 4,005 shares (+80000.0% from 5 pre-transaction).

CEO Seth Lederman purchased 4,000 shares at $21.55 on 2025-05-15, growing his position from 5 shares to 4,005 shares. This represents a substantial increase in absolute dollar exposure ($86,200.00 committed) and an extraordinary percentage gain in holdings. The stock has since risen 35.9% over 30 days and 93.3% over 90 days, yet trades 96.3% below its 52-week high of $631.04, indicating extreme recent volatility. The company reported negative net income of $-16.8M against quarterly revenue of $2.4M, with annual revenue growth of +29.9%, suggesting a loss-making biotech facing scale challenges. The transaction signals leadership capital deployment in a highly volatile pharmaceutical name during a recovery phase in stock price.